Literature DB >> 4855753

Properdin factor D: characterization of its active site and isolation of the precursor form.

D T Fearon, K F Austen, S Ruddy.   

Abstract

The activity of properdin factor D was measured by the generation of the hemolytically active cellular intermediate, EAC43B(D), bearing the C3b-dependent alternate pathway C3 convertase. Treatment of factor D with DFP prevented formation of EAC43B(D); thus, a serine esterase is essential for the generation of the alternate pathway C3 convertase, a situation analogous to the role of C1 in the formation of the classical C3 convertase, C42. The definition of factor D as a serine esterase prompted a search for its proenzyme form, and resulted in the chromatographic isolation from plasma of a single peak of trypsin-inducible factor D activity, distinct from activated factor D. Analytical gel filtration indicated an apparent mol wt of 25,000. This protein from which trypsin elaborated factor D activity, as assessed by the formation of EAC43B(D), the generation of the CoVF-dependent C3 convertase, and the cleavage of factor B in the presence of C3b, was designated "precursor factor D." The DFP resistance of precursor factor D, and the susceptibility of its trypsin-activated form to inactivation by DFP is analogous to the behavior of other plasma serine esterases, including C1.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4855753      PMCID: PMC2139519          DOI: 10.1084/jem.139.2.355

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  20 in total

1.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

2.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

3.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

4.  Some physical-chemical properties of chicken gamma-globulins and their pepsin and papain digestion products.

Authors:  H S Tenenhouse; H F Deutsch
Journal:  Immunochemistry       Date:  1966-01

5.  Functional relationship of factor B in the properdin system to C3 proactivator of human serum.

Authors:  I Goodkofsky; I H Lepow
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

7.  C3b inactivator of man. 3. Further purification and production of antibody to C3b INA.

Authors:  S Ruddy; L G Hunsicker; K F Austen
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

8.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

9.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

10.  C3 proactivator convertase and its mode of action.

Authors:  H J Müller-Eberhard; O Götze
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

View more
  40 in total

1.  Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro.

Authors:  C Bentley; W Fries; V Brade
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

2.  Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.

Authors:  S Ruddy; K F Austen; E J Goetzl
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

3.  Deficiency of factor B of the complement system in sickle cell anaemia.

Authors:  W A Wilson; G R Hughes; P J Lachmann
Journal:  Br Med J       Date:  1976-02-14

4.  Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement.

Authors:  Nirmal K Banda; Minoru Takahashi; Kazue Takahashi; Gregory L Stahl; Stephanie Hyatt; Magdalena Glogowska; Timothy A Wiles; Yuichi Endo; Teizo Fujita; V Michael Holers; William P Arend
Journal:  Mol Immunol       Date:  2011-09-23       Impact factor: 4.407

5.  Prevention of immune precipitation by purified components of the alternative pathway.

Authors:  J K Naama; E Holme; E Hamilton; K Whaley
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

6.  Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes.

Authors:  H U Lutz; F Bussolino; R Flepp; S Fasler; P Stammler; M D Kazatchkine; P Arese
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

7.  Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species.

Authors:  V Brade; L Dieminger; G Schmidt; W Vogt
Journal:  Immunology       Date:  1976-02       Impact factor: 7.397

8.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

9.  Further studies of the adjuvant properties of homologous IgG split products: mode of action of F(ab')2 and related fragments.

Authors:  A J Kulberg; L M Bartova; D N Evnin
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

10.  Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D.

Authors:  Minoru Takahashi; Yumi Ishida; Daisuke Iwaki; Kazuko Kanno; Toshiyuki Suzuki; Yuichi Endo; Yoshimi Homma; Teizo Fujita
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.